Pre-therapy Initial Dosimetry Results of Lu-177-DOTA-617-PSMA In Castration Resistant Prostate Cancer

被引：0
|
作者：
Abuqbeitah, M. M. [1 ]
Yeyin, N. [1 ]
Aygun, A. [1 ]
Demirci, E. [1 ]
Ocak, M. [1 ]
Demir, M. [1 ]
Kabasakal, L. [1 ]
机构：
[1] Istanbul Univ, Istanbul, Turkey
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2015年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P862
引用
收藏
页码：S752 / S752
页数：1
相关论文
共 50 条
  • [1] Dosimetry Results of Lu-177-DKFZ-PSMA-617 Treatment in Castration Resistant Prostate Cancer Patients
    Yeyin, N.
    Mohammad, A.
    Kabasakal, L.
    Demirci, E.
    Aygun, A.
    Ocak, M.
    Toklu, T.
    Tanyildizi, H.
    Selcuk, N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S59 - S59
  • [2] Promising 177Lu-PSMA-617 Therapy Results in Patients with Metastatic Castration-Resistant Prostate Cancer
    Brnjic, Antonio
    Frye, Sarah
    Botkin, Crystal
    Osman, Medhat
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [3] 177Lu-PSMA-617 Therapy in a Case of Metastatic Castration-Resistant Prostate Cancer
    Qu, Gengcuo
    Hua, Qingchu
    Li, Hongmei
    Zhang, Yu
    Chen, Yue
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (02) : 152 - 153
  • [4] 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer
    Fendler, Wolfgang P.
    Kratochwil, Clemens
    Ahmadzadehfar, Hojjat
    Rahbar, Kambiz
    Baum, Richard P.
    Schmidt, Matthias
    Pfestroff, Andreas
    Luetzen, Ulf
    Prasad, Vikas
    Heinzel, Alexander
    Heuschkel, Martin
    Ruf, Juri
    Bartenstein, Peter
    Krause, Bernd J.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2016, 55 (03): : 123 - 128
  • [5] Safety and dosimetry of 177Lu-EB-PSMA617 in patients with metastatic castration-resistant prostate cancer
    Zang, Jie
    Wang, Hao
    Liu, Qingxing
    Jacobson, Orit
    Niu, Gang
    Zhu, Zhaohui
    Chen, Xiaoyuan
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [6] Personalized dosimetry assessment of [177Lu]Lu-PSMA-617 radioligand therapy in the management of metastatic castration-resistant prostate cancer
    Kazemi-Jahromi, Mahmood
    Yazdani, Elmira
    Karamzade-Ziarati, Najme
    Asadi, Mahboobeh
    Sadeghi, Mahdi
    Geramifar, Parham
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2024, 100 (11) : 1551 - 1559
  • [7] Intermittent Radioligand Therapy with 177Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
    Mader, Nicolai
    Schoeler, Christina
    Pezeshkpour, Niloufar
    Klimek, Konrad
    Groener, Daniel
    Happel, Christian
    Tselis, Nikolaos
    Mandel, Philipp
    Gruenwald, Frank
    Sabet, Amir
    CANCERS, 2023, 15 (18)
  • [8] Comment on, 177Lu-PSMA-617 in metastatic, castration-resistant prostate cancer"
    Radtke, Jan Philipp
    Albers, Peter
    Giesel, Frederik Lars
    AKTUELLE UROLOGIE, 2022, 53 (02)
  • [9] Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in treatment of patients with castration resistant prostate cancer
    Yadav, Madhav
    Ballal, Sanjana
    Tripathi, Madhavi
    Damle, Nishikant
    Sahoo, Ranjit
    Roesch, Frank
    Bal, Chandrasekhar
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [10] Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: A substudy of the VISION trial
    Kurth, Jens
    Herrmann, Ken
    Eiber, Matthias
    Rahbar, Kambiz
    Heuschkel, Martin
    Lassmann, Michael
    Jentzen, Walter
    Chicco, Daniela
    Messmann, Richard
    Sartor, A. Oliver
    Morris, Michael J.
    Krause, Bernd J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345